• Selin Aktürk Esen, Sefika Karabulut, Muge Buyukaksoy, Gulnaz Kurt Cevik, Furkan Ceylan, Burak Civelek, ŞendurMehmet Ali NahitMANMedical Oncology Clinic, Ankara Bilkent City Hospital, Ankara, Turkey., Fazli Erdogan, and Doğan Uncu.
• Medical Oncology Clinic, Ankara Bilkent City Hospital, Ankara, Turkey.
• Medicine (Baltimore). 2024 Mar 29; 103 (13): e37656e37656.

AbstractThe prognostic role of fibroblast growth factor 11 (FGF11) has only been reported in cancers such as nasopharyngeal carcinoma and prostate cancer. The role of FGF11 in breast cancer is not fully known. It was aimed to compare FGF11 expression levels in de novo metastatic hormone receptor-positive, human epidermal reseptor-2-negative breast tumor tissue and healthy breast tissue and investigate the effect of the FGF11 expression on survival in breast cancer patients. To determine the FGF11 expression rate, breast tumor tissue of breast cancer patients diagnosed by breast biopsy and healthy breast tissue of healthy individuals who underwent breast biopsy due to benign lesions were used. The study population included 38 breast cancer patients and 24 healthy controls. The number of patients with a FGF11 expression level score of 1 (15.8% vs 12.5%), score of 2 (18.4% vs 12.5%), and score of 3 (31.6% vs 0%) was significantly higher in the patient group compared to the healthy control group. The median overall survival and progression-free survival were numerically better in the group with a FGF11 expression score of 0 to 1 than the group with a FGF11 expression score of 2 and 3, but this difference was not statistically significant. FGF11 may be a predictive marker for breast cancer formation. Additionally, with new FGF11-targeted treatment agents to be developed, endocrine resistance may be reduced, and better survival results may be achieved in hormone receptor-positive, human epidermal reseptor-2-negative breast cancer.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

13 keywords...

hide…